Reduced clone size upon BTK inhibitor resistance mutations relates to toxicity caused by inherited PLCG2 gain-of-function variations

Eur J Haematol. 2024 Jul;113(1):130-131. doi: 10.1111/ejh.14204. Epub 2024 Mar 26.
No abstract available

Publication types

  • Letter

MeSH terms

  • Agammaglobulinaemia Tyrosine Kinase* / antagonists & inhibitors
  • Agammaglobulinaemia Tyrosine Kinase* / genetics
  • Drug Resistance, Neoplasm / genetics
  • Gain of Function Mutation*
  • Humans
  • Mutation
  • Phospholipase C gamma* / genetics
  • Protein Kinase Inhibitors* / therapeutic use

Substances

  • Agammaglobulinaemia Tyrosine Kinase
  • BTK protein, human
  • Phospholipase C gamma
  • Protein Kinase Inhibitors